July 27, 2026 argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline
July 23, 2026 argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update
Follow us
Get the latest news and info via our social media channels.